[Skip to Content]
[Skip to Content Landing]
Editorial
June 2015

A Reassuring Rejoinder Against Malignant Influences of Topical Calcineurin Use in Children

Author Affiliations
  • 1Department of Dermatology, Oregon Health and Science University, Portland
 

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Dermatol. 2015;151(6):587-588. doi:10.1001/jamadermatol.2014.4306

The topical calcineurin inhibitors tacrolimus and pimecrolimus are useful and effective anti-inflammatory immunomodulator adjuncts in managing atopic dermatitis (AD). Unfortunately, because of the increased risk of lymphoma in transplant recipients receiving systemic tacrolimus and because of malignant neoplasms in animal studies with pimecrolimus, their use as topical agents has raised concerns.1 Yet the topical use of these drugs in humans since the mid-1990s has not appeared to cause any clear immunosuppressive propensity toward malignancy.

×